Douglas Bryant, former president and CEO of QuidelOrtho, was fired by the board to boost operational efficiency, revenue, and shareholder value.
Douglas Bryant, the longtime president and CEO of the local biotechnology company QuidelOrtho, was fired on Wednesday. The announcement states that the decision made by the company's board of directors aims to increase operational efficiency, spur revenue growth, and deliver shareholder value.
In addition, Bryant, who led the company as CEO for nearly 15 years, left the board on Wednesday. According to an SEC filing, he will get all benefits and severance payments as specified in his contract.
He was fired a week after the business revealed its underwhelming fourth-quarter and year-end financial results. Following the release of Quidel's earnings on February 13, the company's stock price dropped by 32% as their guidance for 2024 also failed to meet investor expectations.
Investors are probably relieved by the leadership transition "after what can be described as a messy pandemic unwind," according to Raymond James analyst Andrew Cooper in a research note.
QuidelOrtho creates and produces diagnostic tools to support medical practitioners in diagnosing and treating patients for chronic illnesses, infectious diseases, and clinical research. The company insignia, located atop the Western Metal Supply building bricks, is also recognizable to Padres fans.
The U.S. Food and Drug Administration granted Quidel the first emergency use authorization in May 2020 for its COVID-19 antigen test that can be taken home. The company's revenue increased initially, but as the pandemic ended and test demand declined, it eventually decreased.
